Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2023 Filed Jul 6, 2023 12:27 UTC |
GALLIGAN JOSEPH JDirector · 10% owner
|
GrantCommon Stock, par value $0.001 | 2,891 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005033 · form4.xml · nonDerivative · entry 5 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,261 F5 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.73. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:15 UTC |
Lucido Louis C.Director · 10% owner
|
OtherCommon Stock, par value $0.001 | 183,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-002273 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 459,885 F2 · kind: These shares were issued to Mr. Lucido pursuant to an exchange agreement by and between BioCorRx Inc. (the "Company") and Mr. Lucido dated April 3, 2023 (the "Exchange Agreement"). Pursuant to the Exchange Agreement, the Company agreed to issue 183,606 shares of its common stock, par value $0.001 per share, to Mr. Lucido and Mr. Lucido agreed to exchange, surrender and cancel that certain promissory note dated November 1, 2022 held by Mr. Lucido in the aggregate amount of $313,892, including interest. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:15 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 171,296 | $1.75 | $299,768.00 |
DisclosureSEC source: 0001477932-23-002273 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 276,279 F1 · kind: These shares were issued to the Louis C Lucido and Carolyn M. Lucido, or their Successors, as Trustee of the Lucido Family Trust, Dated May 23, 2017, managed by Mr. Louis C Lucido (the "Lucido Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Lucido Trust dated March 29 2023, and paid for on April 3, 2023. The Reporting Person may be deemed to have investment power over the Lucido Trust. F1 · ownership.nature: These shares were issued to the Louis C Lucido and Carolyn M. Lucido, or their Successors, as Trustee of the Lucido Family Trust, Dated May 23, 2017, managed by Mr. Louis C Lucido (the "Lucido Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Lucido Trust dated March 29 2023, and paid for on April 3, 2023. The Reporting Person may be deemed to have investment power over the Lucido Trust. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 22:31 UTC |
Ingargiola LuisaDirector
|
GrantCommon Stock, par value $0.001 | 2,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-002229 · form4.xml · nonDerivative · entry 1 Ingargiola Luisa · CIK 0001447277 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,499 F1 · kind: These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.77. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 22:44 UTC |
Murthy HarshaDirector
|
GrantCommon Stock, par value $0.001 | 2,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-002231 · form4.xml · nonDerivative · entry 1 Murthy Harsha · CIK 0001962250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,231 F1 · kind: These shares were issued to Mr. Murthy pursuant to a Director Agreement, dated January 20, 2023, by and between BioCorRx Inc. and Mr. Murthy. As compensation for his services, Mr. Murthy shall be issued, upon the last day of each fiscal quarter, provided Mr. Murthy is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter; however, the number of shares issued to Mr. Murthy for such fiscal quarter is equivalent to a prorated amount of $3,948.72 to account for the number of days Mr. Murthy served as a member of the Board during such fiscal quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.77. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 22:29 UTC |
Lucido Louis C.Director · 10% owner
|
GrantCommon Stock, par value $0.001 | 2,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-002226 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,983 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.77. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 22:29 UTC |
Granier Brady JamesDirector · President
|
GrantStock Option · Derivative | 8,472 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001477932-23-002225 · form4.xml · derivative · entry 1 Granier Brady James · CIK 0001570636 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,472 Underlying: Common Stock · 8,472 shares Expires 2028-03-31 F1 · shares: On March 31, 2023, the issuer granted the reporting person an option that was 100% vested on issuance. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 22:28 UTC |
Felix LourdesDirector · CEO and CFO
|
GrantCommon Stock, par value $0.001 | 2,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-002224 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,907 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.77. Read SEC document |
| March 31, 2023 Filed Jul 5, 2023 21:05 UTC |
Emry KentDirector
|
GrantCommon Stock, par value $0.001 | 2,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005021 · form4.xml · nonDerivative · entry 1 Emry Kent · CIK 0001589628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,316 F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.77. Read SEC document |
| March 31, 2023 Filed Jul 6, 2023 12:27 UTC |
GALLIGAN JOSEPH JDirector · 10% owner
|
GrantCommon Stock, par value $0.001 | 2,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005033 · form4.xml · nonDerivative · entry 4 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,370 F4 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.77. Read SEC document |
| March 29, 2023 Filed Jul 6, 2023 12:27 UTC |
GALLIGAN JOSEPH JDirector · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 171,296 | $1.75 | $299,768.00 |
DisclosureSEC source: 0001477932-23-005033 · form4.xml · nonDerivative · entry 3 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 217,546 F3 · kind: These shares were issued to The J and R Galligan Revocable Trust, managed by Mr. Joseph M. Galligan (the "Galligan Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Galligan Trust dated March 29 2023, and paid for on March 30, 2023. The Reporting Person may be deemed to have investment power over the Galligan Trust. F3 · ownership.nature: These shares were issued to The J and R Galligan Revocable Trust, managed by Mr. Joseph M. Galligan (the "Galligan Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Galligan Trust dated March 29 2023, and paid for on March 30, 2023. The Reporting Person may be deemed to have investment power over the Galligan Trust. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:15 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 100 | $1.37 | $137.00 |
DisclosureSEC source: 0001477932-23-000644 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,159 Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:15 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 300 | $1.39 | $417.00 |
DisclosureSEC source: 0001477932-23-000644 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,059 Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:15 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 500 | $1.29 | $646.50 |
DisclosureSEC source: 0001477932-23-000587 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,759 Read SEC document |
| January 24, 2023 Filed Jan 25, 2023 19:32 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 200 | $1.20 | $240.00 |
DisclosureSEC source: 0001477932-23-000530 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,259 Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 21:15 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 2,000 | $1.15 | $2,300.00 |
DisclosureSEC source: 0001477932-23-000335 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,059 Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 21:15 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 2,000 | $1.10 | $2,200.00 |
DisclosureSEC source: 0001477932-23-000335 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,059 Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:16 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 2,000 | $1.10 | $2,200.00 |
DisclosureSEC source: 0001477932-23-000088 · form4.xml · nonDerivative · entry 4 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,059 Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:16 UTC |
Lucido Louis C.Director · 10% owner
|
GrantCommon Stock, par value $0.001 | 5,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000088 · form4.xml · nonDerivative · entry 3 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,059 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.94 Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:16 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 115 | $1.03 | $118.45 |
DisclosureSEC source: 0001477932-23-000088 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,740 Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:16 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 200 | $0.98 | $195.00 |
DisclosureSEC source: 0001477932-23-000088 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,625 Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:15 UTC |
Granier Brady JamesDirector · President
|
GrantStock Option · Derivative | 15,957 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001477932-23-000089 · form4.xml · derivative · entry 1 Granier Brady James · CIK 0001570636 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,957 Underlying: Common Stock · 15,957 shares Expires 2027-12-30 F1 · shares: On December 30, the issuer granted the reporting person an option that was 100% vested on issuance. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:15 UTC |
Felix LourdesDirector · CEO and CFO
|
GrantCommon Stock, par value $0.001 | 5,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000087 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,083 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.94. Read SEC document |
| December 30, 2022 Filed Jan 6, 2023 12:09 UTC |
Emry KentDirector
|
GrantCommon Stock, par value $0.001 | 5,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000145 · form4.xml · nonDerivative · entry 3 Emry Kent · CIK 0001589628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,492 F3 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.94. Read SEC document |
| December 30, 2022 Filed Jan 9, 2023 15:02 UTC |
Ingargiola LuisaDirector
|
GrantCommon Stock, par value $0.001 | 5,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000179 · form4.xml · nonDerivative · entry 1 Ingargiola Luisa · CIK 0001447277 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,675 F1 · kind: These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.94. Read SEC document |
| December 30, 2022 Filed Jul 6, 2023 12:27 UTC |
GALLIGAN JOSEPH JDirector · 10% owner
|
GrantCommon Stock, par value $0.001 | 5,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005033 · form4.xml · nonDerivative · entry 2 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,250 F2 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.94. Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 12:29 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 2,000 | $0.80 | $1,600.00 |
DisclosureSEC source: 0001477932-22-009312 · form4.xml · nonDerivative · entry 4 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,425 Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 12:29 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 1,000 | $0.80 | $800.00 |
DisclosureSEC source: 0001477932-22-009312 · form4.xml · nonDerivative · entry 3 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,425 Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 12:29 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 1,000 | $0.98 | $980.00 |
DisclosureSEC source: 0001477932-22-009312 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,425 Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 12:29 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 1,000 | $0.79 | $790.00 |
DisclosureSEC source: 0001477932-22-009312 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,425 Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 21:59 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 100 | $1.73 | $173.00 |
DisclosureSEC source: 0001477932-22-007543 · form4.xml · nonDerivative · entry 5 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,425 Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 21:59 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 120 | $1.90 | $228.00 |
DisclosureSEC source: 0001477932-22-007543 · form4.xml · nonDerivative · entry 4 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,325 Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 21:59 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 360 | $1.90 | $684.00 |
DisclosureSEC source: 0001477932-22-007543 · form4.xml · nonDerivative · entry 3 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,205 Read SEC document |
| October 05, 2022 Filed Oct 11, 2022 21:59 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 1,000 | $2.02 | $2,020.00 |
DisclosureSEC source: 0001477932-22-007543 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,845 Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 19:48 UTC |
Ingargiola LuisaDirector
|
GrantCommon Stock, par value $0.001 | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-007466 · form4.xml · nonDerivative · entry 1 Ingargiola Luisa · CIK 0001447277 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,356 F1 · kind: These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.04. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 20:08 UTC |
Lucido Louis C.Director · 10% owner
|
GrantCommon Stock, par value $0.001 | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-007471 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,835 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.04. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 20:08 UTC |
Granier Brady JamesDirector · President
|
GrantStock Option · Derivative | 7,350 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001477932-22-007470 · form4.xml · derivative · entry 1 Granier Brady James · CIK 0001570636 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,350 Underlying: Common Stock · 7,350 shares Expires 2027-09-30 F1 · shares: On September 30, 2022, the issuer granted the reporting person an option that was 100% vested on issuance. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 19:48 UTC |
Felix LourdesDirector · CEO and CFO
|
GrantCommon Stock, par value $0.001 | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-007465 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,764 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.04. Read SEC document |
| September 30, 2022 Filed Jan 6, 2023 12:09 UTC |
Emry KentDirector
|
GrantCommon Stock, par value $0.001 | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000145 · form4.xml · nonDerivative · entry 2 Emry Kent · CIK 0001589628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,173 F2 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.04. Read SEC document |
| September 30, 2022 Filed Jul 6, 2023 12:27 UTC |
GALLIGAN JOSEPH JDirector · 10% owner
|
GrantCommon Stock, par value $0.001 | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005033 · form4.xml · nonDerivative · entry 1 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,931 F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.04. Read SEC document |
| September 06, 2022 Filed Oct 11, 2022 21:59 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 10 | $2.10 | $21.00 |
DisclosureSEC source: 0001477932-22-007543 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,845 Read SEC document |
| August 31, 2022 Filed Aug 31, 2022 23:15 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 610 | $2.12 | $1,293.20 |
DisclosureSEC source: 0001477932-22-006572 · form4.xml · nonDerivative · entry 3 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,385 Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 23:15 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 2,268 | $2.10 | $4,762.80 |
DisclosureSEC source: 0001477932-22-006572 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,775 Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 23:15 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 1,000 | $2.12 | $2,120.00 |
DisclosureSEC source: 0001477932-22-006572 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,507 Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 16:16 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 560 | $2.12 | $1,187.20 |
DisclosureSEC source: 0001477932-22-006484 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,507 Read SEC document |
| August 25, 2022 Filed Aug 29, 2022 16:16 UTC |
Lucido Louis C.Director · 10% owner
|
PurchaseCommon Stock, par value $0.001 | 500 | $2.18 | $1,090.00 |
DisclosureSEC source: 0001477932-22-006484 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,947 Read SEC document |
| June 30, 2022 Filed Jul 7, 2022 22:06 UTC |
Lucido Louis C.Director · 10% owner
|
GrantCommon Stock, par value $0.001 | 2,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-004884 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,447 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.39. Read SEC document |
| June 30, 2022 Filed Jul 7, 2022 22:05 UTC |
Ingargiola LuisaDirector
|
GrantCommon Stock, par value $0.001 | 2,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-004882 · form4.xml · nonDerivative · entry 1 Ingargiola Luisa · CIK 0001447277 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,906 F1 · kind: These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.39. Read SEC document |
| June 30, 2022 Filed Jul 7, 2022 22:06 UTC |
Felix LourdesDirector · CEO and CFO
|
GrantCommon Stock, par value $0.001 | 2,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-004883 · form4.xml · nonDerivative · entry 1 Felix Lourdes · CIK 0001569735 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,314 F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.39. Read SEC document |
| June 30, 2022 Filed Jul 8, 2022 10:02 UTC |
GALLIGAN JOSEPH JDirector · 10% owner
|
GrantCommon Stock, par value $0.001 | 2,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-004886 · form4.xml · nonDerivative · entry 1 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,481 F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.39. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.